Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Allantoin + coal tar + clioquinol** is a topical pharmaceutical combination developed primarily for the treatment of dermatological conditions associated with scaling, inflammation, and microbial involvement, such as psoriasis and seborrheic dermatitis. - **Allantoin** acts as a skin protectant and keratoplastic, promoting skin healing and normal keratinization. - **Coal tar** is a keratolytic agent that reduces scaling, itching, and inflammation by suppressing DNA synthesis and retarding cell proliferation in hyperactive skin. - **Clioquinol** serves as an antimicrobial, targeting potential secondary infections by inhibiting the growth of bacteria and fungi. The combination can be formulated as a shampoo or lotion and may include additional agents such as triclosan. A notable marketed product is Sebryl Plus. Clinical evidence and patents support its effectiveness in rapidly reducing scaling and redness in psoriasis and related dermatoses[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allantoin + coal tar + clioquinol.